

Journal of Visualized Experiments

A freeze-thawing method to prepare chitosan-poly (vinyl alcohol) hydrogels without crosslinking agents and diflunisal release studies

--Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE59636R2
Full Title:	A freeze-thawing method to prepare chitosan-poly (vinyl alcohol) hydrogels without crosslinking agents and diflunisal release studies
Keywords:	Chitosan-Poly(vinyl alcohol) hydrogels; Freeze-thawing; Diflunisal; Drug loading and release studies; Network characterization; Porosimetry.
Corresponding Author:	María Elisa Martínez-Barbosa Universidad de Sonora HERMOSILLO, Sonora MEXICO
Corresponding Author's Institution:	Universidad de Sonora
Corresponding Author E-Mail:	memartinez@polimeros.uson.mx
Order of Authors:	María Dolores Figueroa-Pizano Itziar Vélaz María Elisa Martínez-Barbosa
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Mexico City

TITLE:

A Freeze-Thawing Method to Prepare Chitosan-Poly(vinyl alcohol) Hydrogels Without Crosslinking Agents and Diflunisal Release Studies

AUTHORS AND AFFILIATIONS:

M. D. Figueroa-Pizano¹, I. Vélaz^{2*}, M. E. Martínez-Barbosa^{1*}

¹Department of Polymers and Materials, University of Sonora, Hermosillo, Sonora, Mexico

²Department of Chemistry, Faculty of Sciences, University of Navarra, C/Irunlarrea s/n, Pamplona, Navarra, Spain

Corresponding Author:

M. E. Martínez-Barbosa

elisa.martinez@unison.mx

I. Vélaz

itzvelaz@unav.es

Email Addresses of Co-authors:

mariad.figueroap@a2004.uson.mx

KEYWORDS:

Chitosan-Poly(vinyl alcohol) hydrogels, Freeze-thawing, Diflunisal, Drug loading and release studies, Network characterization, Porosimetry

SUMMARY:

The freezing-thawing method is used to produce chitosan-poly(vinyl alcohol) hydrogels without crosslinking agents. For this method, it is important to consider the freezing conditions (temperature, number of cycles) and polymer ratio, which can affect the properties and applications of the obtained hydrogels.

ABSTRACT:

Chitosan-poly(vinyl alcohol) hydrogels can be produced by the freeze-thawing method without using toxic crosslinking agents. The applications of these systems are limited by their characteristics (e.g., porosity, flexibility, swelling capacity, drug loading and drug release capacity), which depend on the freezing conditions and the kind and ratio of polymers. This protocol describes how to prepare hydrogels from chitosan and poly(vinyl alcohol) at 50/50 w/w % of polymer composition and varying the freezing temperature (-4 °C, -20 °C, -80 °C) and freeze-thawing cycles (4, 5, 6 freezing cycles). FT-IR spectra, SEM micrograph and porosimetry data of hydrogels were obtained. Also, the swelling capacity and drug loading and release of diflunisal were assessed. Results from SEM micrographs and porosimetry show that the pore size decreases, while the porosity increases at lower temperatures. The swelling percentage was higher at the minor freezing temperature. The release of diflunisal from the hydrogels has

been studied. All the networks maintain the drug release for 30 h and it has been observed that a simple diffusion mechanism regulates the diflunisal release according to Korsmeyer-Peppas and Higuchi models.

INTRODUCTION:

Recently, hydrogels have attracted great interest in the biomedical field because they are three-dimensional networks with high water content and are soft and flexible, so they can mimic natural tissues easily¹. Also, they do not dissolve in aqueous medium at physiological temperature and pH but present a large swelling². Hydrogels can act as tissue engineering scaffolds, hygiene products, contact lenses, and wound dressings; because they can trap and release active compounds and drugs, they are used as drug delivery systems³. Depending on their application, hydrogels can be made from natural or synthetic polymers, or a combination of both, in order to obtain the best characteristics⁴.

The properties of hydrogels are a consequence of many physical and chemical factors. At the physical level, their structure and morphology depend on their porosity, pore size and pore distribution⁵. At the chemical and molecular level, the polymer type, the hydrophilic group content in the polymer chain, the crosslinking point type, and the cross-linking density are the factors that determine the swelling capacity and the mechanical properties^{6,7}.

According to the type of crosslinking agent used to form the network, the hydrogels are classified as chemical hydrogels or physical hydrogels. Chemical hydrogels are joined by covalent interactions between their chains, which are formed through UV and gamma irradiation or using a crosslinking agent^{7,8}. Chemical hydrogels usually are strong and resistant but, generally, the crosslinking agent is toxic to the cells and its removal is difficult, so its application is limited. On the other hand, physical hydrogels form by the connection of the polymer chains through non-covalent interactions, avoiding the use of crosslinking agents^{4,9}. The main non-covalent interactions in the network are hydrophobic interactions, electrostatic forces, complementary and hydrogen bounds⁷.

Poly(vinyl alcohol) (PVA, **Figure 1a**) is a synthetic and water-soluble polymer with excellent mechanical performance and biocompatibility that can form crosslink agent-free hydrogels through the freeze-thawing method^{10,11}. This polymer has the capacity to form concentrated zones of hydrogen bonds between -OH groups of their chains (crystalline zones) when they are freezing¹². These crystalline zones act as crosslinking points in the network, and they are promoted by two events: the approaching of the polymer chains when the crystal water expands and the PVA conformational changes from isotactic to syndiotactic PVA during freeze¹³. Because of the freeze-drying, the water crystals are sublimated, leaving void spaces that are the pores in the hydrogel¹⁴. To obtain hydrogels with better properties, PVA can be easily combined with other polymers.

In that sense, chitosan constitutes an option as it is the only biopolymer from natural sources with positive charges. It is obtained by the deacetylation of chitin and it is composed of random combinations of β -1,4 linked D-glucosamine (deacetylated unit) and N-acetyl-D-glucosamine

(acetylated unit)^{15,16} (**Figure 1b**). Chitosan is biodegradable by human enzymes and it is biocompatible. Also, by its cationic nature, it can interact with the negative charge of the cell surface, and this property has been associated with its antimicrobial activity¹⁷. This polymer is easy to process; however, their mechanical properties are not sufficient and some materials have been added to form complexes with better characteristics.

Considering specific characteristics of chitosan and PVA, the successful manufacture of hydrogels has been reached by the freeze-thawing method^{2,18} to avoid the use of toxic crosslinking agents. In chitosan-PVA hydrogels, the crystalline zones of PVA are also formed, and chitosan chains are interpenetrated and form simple hydrogen bonds with –NH₂ groups and –OH groups in PVA. The final chitosan-PVA hydrogel is mechanically stable, with high rates of swelling and low toxicity, and with antibacterial effect¹⁸. However, depending on the freezing conditions used in the preparation (temperature, time and number of cycles), the final characteristics may change. Some studies report that increasing the number of freezing cycles decreases the swelling degree and increases the tensile strength^{19,20}. In order to strengthen the network, other agents such as gamma and UV radiation and chemical crosslinkers have been used additionally after the freeze-thawed preparation^{21–23}. Hydrogels with a higher chitosan proportion have a more porous network and high swelling capacity but less strength and thermal stability. In this context, it is important to consider the preparation conditions to obtain suitable hydrogels for their target application.

The purpose of this work is to present in detail how the freezing conditions (temperature of freezing and number of cycles) affect the final characteristics of CS-PVA hydrogels. FT-IR spectra, morphological and porosity characteristics and swelling capacity were evaluated, as well as drug loading and release capacity. In the release studies, diflunisal (**Figure 1-c**) was used as model drug, due to its size suitable to the hydrogel structure.

PROTOCOL:

1. Preparation of chitosan-PVA hydrogels

1.1. Prepare 2% (w/w) chitosan and 10% (w/w) PVA solutions. Dissolve 0.2 g of chitosan in 10 mL of 0.1 M CH₃COOH solution (previously filtered) at room temperature and maintain continuous mechanical stirring overnight. Dissolve 1 g of PVA in 10 mL of distilled water and stir at 80 °C for 1 h.

1.2. Mix both solutions 1:1 using a magnetic stirrer until they are homogeneous at room temperature, and pour the mixtures on Petri dishes. Leave the samples for 2 h at atmospheric pressure to degas.

1.3. Freeze the hydrogels at -4 °C, -20 °C or -80 °C for 20 h and 4 cycles (samples CP4-4, CP4-20 and CP4-80, respectively). Freeze another hydrogel at -80 °C for 20 h using 5 or 6 freezing cycles (samples CP5-80 and CP6-80). After the third freezing cycle, wash the hydrogels with

deionized water. At the end, freeze-dry the hydrogels at -46 °C for 48 h and store for further characterization (methodology adapted from²).

2. FT-IR characterization

2.1 Place a little piece (1 mm x 2 mm) of hydrogel in the FT-IR spectrometer in ATR mode. Take the FT-IR spectra from 4000 to 600 cm⁻¹ (2 cm⁻¹ of resolution and average of 32 scans).

3. Swelling assays

3.1 Cut out discs (13 mm in diameter and 10 mm in height) from the hydrogel and weigh them. Incubate the discs in 50 mL of deionized water with shaking at 25 °C. Repeat three times.

3.2 Every 30 min remove the sample from the medium, blotter to eliminate the excess of water, and weigh. Calculate the swelling degree using the equation 1 and calculate the equilibrium state of swelling, q , at 24 h using the equation 2.

$$SD(\%) = \left[\left(\frac{W_s - W_d}{W_d} \right) \right] * 100 \text{ (Eq. 1)}$$

Where W_d is the weight of the dry hydrogel and W_s is the weight of the wet hydrogel.

$$q = \frac{W_s}{W_d} \text{ (Eq. 2)}$$

4. Electronic Microscopy

4.1 Cover a little piece of hydrogel with a thin gold layer (30 s and 10 mA) in a sputter coater.

4.2 Put the sample in a scanning electron microscope (SEM). Analyze the samples under vacuum at 20 kV and take the images with a 500x and 1500x magnification.

5. Porosimetry

5.1 Place discs 15 mm in diameter weighing around 0.26 g into the penetrometer (a solid penetrometer, having a bulk volume of 0.3660 mL and 5.7831 mL of stem volume). Analyze the porosity and pore size by Mercury Intrusion Porosimetry (MIP).

5.2 Conduct the experiment in the hysteresis mode (intrusion-extrusion). Measure the total intrusion volume (mL/g), total pore area (m²/g), pore diameter (μm), porosity (%), permeability (mDarcy) and tortuosity. Repeat twice.

6. Drug loading and release

173
174 6.1 Before loading, prepare 4 L of 15 mg/L diflunisal solution and stir overnight. Confirm the
175 concentration of the solution by UV-Vis spectroscopy (initial concentration). Indeed, swell 400
176 mg of freeze-dried samples of hydrogel in 6 mL of distilled water for 24 h.

177
178 6.2 For loading, fill a flask with 50 mL of diflunisal solution and maintain at 25 °C with
179 constant stirring. Submerge each swelled hydrogel in the flask.

180
181 6.2.1. Take aliquots of remaining diflunisal solution (2 mL) at different times in order to
182 determine the *plateau* region of the curve, for example: 3, 6, 24, 27, 30 and 48 h. After 24 h
183 replace the solution with a fresh one.

184
185 6.3 Measure the absorbance at 252 nm of each aliquot, and determine the concentration of
186 diflunisal present in the solution, using a calibration curve of diflunisal. Calculate the amount of
187 diflunisal retained in the hydrogel at 24 and 48 h, as the difference of initial and final
188 concentrations, taking into account the total volume (56 mL).

189
190 6.3.1. Determine the encapsulation efficiency (EE) using the equation 3.

191
192
$$EE\% = \frac{\text{Diflunisal concentration inside the hydrogel}}{\text{Diflunisal concentration in the solution}} \times 100 \text{ (Eq. 3)}$$

193
194 6.3.2. Freeze the loaded hydrogels at -80 °C and lyophilize them at -50 °C.

195
196 6.4 For drug release, submerge 30 mg of freeze-dried diflunisal loaded hydrogels in 50 mL of
197 phosphate buffer (pH 7.4) at 25 °C. Maintain constant stirring. Withdraw aliquots of 2 mL at
198 different times and replace with fresh medium to keep a constant volume.

199
200 6.4.1. Determinate the diflunisal released spectrophotometrically at 252 nm, according to a
201 calibration curve.

202
203 6.5 Deduce the predominant drug release mechanism in the hydrogels adjusting the drug
204 release data corresponding to the first 60%, to the Korsmeyer-Peppas model (Equation 4), to
205 obtain the kinetic (k) and the diffusion (n) constants. The n values indicate the mechanism of
206 drug release^{24, 25}. Then, n values close to 0.5 are related to Fickian diffusion, meanwhile values
207 of 0.5-1.0 for anomalous transport, where are involved diffusion and relaxation chains, and
208 finally, values of 1.0 are related to case II transport.

209
210
$$\text{Korsmeyer – Peppas model } \frac{M_t}{M_\infty} = k_{KP} t^n \text{ (Eq. 4)}$$

211
212 6.5.1. To confirm the results, use the Higuchi, First order, and Zero order mathematical models
213 (Equations 5 to 7) and select the better fit.

214 6.5.2.

Higuchi model $Mt/M_{\infty} = k_H t^{0.5}$ (Eq. 5)

First Order model $Mt/M_{\infty} = 1 - e^{-k_1 t}$ (Eq. 6)

Zero Order model $Mt/M_{\infty} = k_0 t$ (Eq. 7)

where t represents the release time, Mt the amount of drug delivered at a given time, and M_{∞} the total amount of drug delivered at the end of the process.

REPRESENTATIVE RESULTS:

Hydrogels preparation

Chitosan-PVA hydrogels were obtained at -4 °C, -20 °C and -80 °C with 4 freezing cycles and at -80 °C with 5 and 6 freezing cycles by the previously reported freeze-thawing method². All hydrogels were homogeneous, semi-transparent, flexible and resistant against manipulation.

FT-IR characterization

The FT-IR spectra are shown in **Figure 2**. Seven characteristics signals of chitosan and PVA polymers were detected: at 3286 cm⁻¹ the stretching vibration mode of PVA hydroxyl group (-OH) and at 2918 cm⁻¹ the stretching vibration mode of -CH group^{26, 27}. The signals of amide groups, representative of chitosan structure, were found at 1652 cm⁻¹ to the stretching vibration mode of C=O (amide I), at 1560 cm⁻¹ to the flexion vibration mode of N-H (amide II) and 1325 cm⁻¹ to the vibration of amide III²⁸⁻³⁰. Other signals, at 1418 cm⁻¹ to the flexion vibration mode of C-H and at 1086 cm⁻¹ to the stretching vibration mode of C-O groups, both of PVA, were detected^{27, 31, 32}.

Electronic Microscopy

All CS-PVA hydrogels showed a highly porous surface (**Figure 3**, from left to right) and distinctive changes were observed according to the preparation conditions. Hydrogels prepared at -4 °C (CP4-4) presented larger pores than the hydrogels prepared at -80 °C (CP4-80). Moreover, the latter appears to have a more porous network. This effect may be due to the fact that, at lower temperature, the water crystal formation was faster and many small crystals emerged and were sublimated during the freeze-drying process, leaving void pores^{14, 33}. Meanwhile, the effect of the number of freezing cycles seems to promote more defined and circular pores in hydrogels CP6-80 (**Figure 3**, from top to bottom).

Porosimetry

Samples CP4-4, CP4-80 and CP6-80 presented more pronounced changes; in order to complement the information about morphology, they were analyzed by MIP (**Table 1**). The comparison between hydrogels CP4-4 and CP4-80 (**Figure 3-a**) showed that, at a lower temperature of freezing, hydrogels developed a more porous network, which presented a large total intrusion volume and higher total pore area. However, hydrogels CP6-80 showed less permeability than CP4-80 (**Figure 3-b**), probably due to their high tortuosity, which was also

reflected in a lower total intrusion volume. **Figure 3** presents the different pore sizes of these hydrogels. Two pore sizes were distinguished, one between 0.3-5.0 μm and other between 5.0-30 μm . In hydrogels CP4-80 and CP6-80, the porous network had a greater number of small pores than large ones, compared with CP4-4 hydrogel. These results were similar to those observed by SEM micrographs and suggested that, at lower temperature greater interactions between the PVA chains were favored and more crystalline zones were formed. In such a way, the formation of crystalline zones by PVA chains, was stimulated at low temperature.

Swelling assays

The swelling behavior of CS-PVA hydrogels can be seen in the **Figure 4**. They quickly absorbed large amounts of water; for the first 5 hours they retained 10x their weight, and after 20 hours they retain up to 15x their weight (equilibrium point). However, in relation to hydrogels prepared at the same number of freezing cycles, the hydrogel CP4-80 showed less swelling capacity in the first 5 hours as a consequence of the temperature that was used for its preparation ($-80\text{ }^{\circ}\text{C}$). In the case of hydrogels prepared at different number of freezing cycles (CP4-80, CP5-80 and CP6-80) no differences were found at any time. Probably, the decreased swelling capacity observed in hydrogels prepared at $-80\text{ }^{\circ}\text{C}$ was caused by the small pore size of the hydrogel network.

Drug loading and release

To evaluate the capacity of CS-PVA hydrogels as drug delivery systems, the anti-inflammatory drug diflunisal was loaded in the network and subsequently released. The encapsulation efficiency (EE) in all these systems was around 70%; however, the CP4-80 hydrogel presented more slightly EE at 73% (**Table 2**). Meanwhile, the releasing kinetics of diflunisal from the CS-PVA hydrogels were maintained for about 30 h in all cases. The CP4-80 hydrogel released the highest amount of diflunisal (**Figure 5**). This may be due to the fact this hydrogel showed a more porous structure in comparison with the other two types of hydrogel. This feature allowed the small molecule of drug to easily enter in the hydrogel network and, then, to be released. Between CP4-80 and CP6-80 hydrogels not differences were observed during release times (**Figure 6**). No *burst* effect was observed in any of the CS-PVA hydrogels, which is promising for pharmaceutical applications. Mathematical models were used to determine the main release mechanism in CS-PVA hydrogels. The results were adjusted to different mathematical models (**Table 3**) and according to the n values, it was found that the Fick diffusion dominates the drug release process.

FIGURE AND TABLE LEGENDS:

Figure 1 Chemical structure of PVA (a), chitosan (b) and diflunisal (c).

Figure 2 FT-IR spectra of pure chitosan and PVA and, chitosan-PVA hydrogels prepared at different conditions of freezing.

Figure 3 SEM micrographs of chitosan-PVA hydrogels at 1500x magnification. Pore size distributions of chitosan-PVA hydrogels: a) hydrogels prepared with 4 cycles of freezing and at -

4 °C and -80 °C. **b)** Hydrogels prepared at -80 °C and, 4 and 6 cycles.

Figure 4 Swelling kinetics of chitosan-PVA hydrogels: **a)** hydrogels with 4 cycles of freezing and **b)** hydrogels prepared at -80 °C.

Figure 5 Diflunisal release profiles in mg **(a)** and M_t/M_∞ **(b)** for hydrogels CP4-4 and CP4-80.

Figure 6 Diflunisal release profiles in mg **(a)** and M_t/M_∞ **(b)** for hydrogels CP4-80 and CP6-80.

Table 1 Porosimetry parameters of the porous structure of chitosan-PVA hydrogels.

Table 2 Encapsulation and release efficiencies for chitosan-PVA hydrogels.

Table 3 Kinetic parameters of diflunisal release from chitosan-PVA hydrogels.

DISCUSSION:

The freeze-thawing method is a suitable process to prepare biocompatible hydrogels focused in biomedical, pharmaceutical or cosmetical applications^{34–36}. The most important advantage of this method, compared with other well-known methods to prepare hydrogels, is that crosslinking agent use is avoided, which could cause an inflammatory response or adverse effects in the human body³⁴. This is a versatile method because it offers the possibility to prepare hydrogels from PVA or their mixtures with different polymers^{11,37} in such way that new characteristics from the other polymers can be obtained in the new material (e.g., major capacity to absorb water, antimicrobial or antioxidant properties^{2,18,35}). However, it is important to consider that the incorporation of other polymers could decrease the strength of the hydrogels^{19,37}.

The principal parameters to consider in the freeze-thawing method are the temperature of freezing, the time and the number of freezing cycles, and also, the polymer ratio (in case of polymer mixtures)^{2,19,20}. A wide range of swelling, morphological and mechanical properties can be obtained with this method when the freeze conditions are controlled. These parameters affect directly the three-dimensional network configuration in chitosan-PVA hydrogels because the freezing conditions promotes the arrangements in PVA chains, which are joined by physical interactions, called crystalline zones^{12,38}. These crystalline zones are concentrated regions of hydrogen bonds that act as crosslinking points in the hydrogels, which maintain and form the three-dimensional network and it is a retractor force when hydrogels are in the swelling state^{2,39,40}.

In this study, we evaluated the effect of a new range of freeze-thawing temperatures (-4 °C, -20 °C and -80 °C) combined with a different number of freezing cycles (4, 5 and 6) but the same time of freezing (20 h), to prepare 1:1 chitosan-PVA hydrogels. The lowest swelling capacity was observed at the lowest temperature (-80 °C). Indeed, hydrogels at this lowest temperature obtained the smaller pores and the more porous networks. These differences in chitosan-PVA hydrogels are useful for different applications such as drug delivery systems or scaffolds. In

general, chitosan-PVA hydrogels present high rates of swelling, due to chitosan hydrophilic groups ($-\text{NH}_2$)^{41,42}, and they are soft, flexible, easy to handle and resist the manipulation because of PVA characteristics. In that sense, the freeze-thawing method is easy, cheap and fast to produce chitosan-PVA hydrogels with different properties, avoiding toxic crosslinking.

Although the freeze-thawing is an easy and friendly method, it has some drawbacks. A complete homogenization of chitosan, in this case, and of the polymer mixtures is very important. Hydrogels can present more fragile zones and an irregular porous structure. Also, it is necessary to make a correct dissolution of PVA in water by heating at 70-80 °C^{42, 43} for 1 h under magnetic stirring. The cooling of this PVA solution must be slow with constant stirring to prevent the formation of a solid layer of PVA.

A limitation of this method, for cell culture assays, is the formation of whitish or semitransparent hydrogels. In this case, the application of glycerol or DMSO (toxic compound at room temperature) could be used to improve the appearance of hydrogel^{23,44}. The freeze-drying step of the freeze-thawing method to prepare CS-PVA hydrogels is a critical step, because the hydrogels could present a constriction in the middle zone, which complicate the work and the characterization. To avoid this, the sample must be kept completely frozen before lyophilization. Concerning the drug loading and release studies, it is very important to ensure that there is no interference with the signals from the hydrogel components and the drug to be quantified.

ACKNOWLEDGMENTS:

Authors are grateful to C. Luzuriaga for the support in the porosimetry measurements. Authors also thanks to Ministerio de Economía y Competitividad of Spain for financial support (Project MAT2014-59116-C2-2-R) and PIUNA (ref. 2018-15). The authors also would like to acknowledge Dr. Amir Maldonado from Departamento de Física-UNISON for support and helpful comments and Dr. SE Burrueal-Ibarra from DIPM-UNISON for SEM images and Rubio Pharma y Asociados S. A. de C. V. for financial support. ME Martínez-Barbosa would like to thank CONACyT (México) projects No. 104931 and No. 256753, besides the financial support from Red Temática de Nanociencias y Nanotecnología del programa de Redes Temáticas del CONACyT. And, also project USO316001081. MD Figueroa-Pizano would like to acknowledge CONACyT for financial support (scholarship 373321).

DISCLOSURES:

The authors have nothing to disclose.




REFERENCES:


1. Gyles, D.A., Castro, L.D., Silva, J.O.C., Ribeiro-Costa, R.M. A review of the designs and prominent biomedical advances of natural and synthetic hydrogel formulations. *European Polymer Journal*. **88** (01), 373–392 (2017).
2. Abdel-Mohsen, a. M., Aly, a. S., Hrdina, R., Montaser, a. S., Hebeish, a. Eco-Synthesis of PVA/Chitosan Hydrogels for Biomedical Application. *Journal of Polymers and the Environment*. **19**, 1005–1012 (2011).


3. Caló, E., Khutoryanskiy, V. V. Biomedical applications of hydrogels: A review of patents and commercial products. *European Polymer Journal*. **65**, 252–267 (2015).
4. Ahmadi, F., Oveisi, Z., Samani, M., Amoozgar, Z. Chitosan based hydrogels: Characteristics and pharmaceutical applications. *Research in Pharmaceutical Sciences*. **10** (1), 1–16 (2015).
5. Siepmann, J., Siegel, R.A., Rathbone, M.J. *Fundamentals and applications of controlled release drug delivery. Fundamentals and Applications of Controlled Release Drug Delivery* (2012).
6. Gulrez, S.K.H., Al-Assaf, S., Phillips, O, G. Hydrogels: Methods of Preparation, Characterisation and Applications. *Progress in Molecular and Environmental Bioengineering - From Analysis and Modeling to Technology Applications*. 117–146 (2011).
7. Ahmed, E.M. Hydrogel: Preparation, characterization, and applications. *Journal of Advanced Research*. **6** (2), 105–121 (2015).
8. Deligkaris, K., Tadele, T.S., Olthuis, W., van den Berg, A. Hydrogel-based devices for biomedical applications. *Sensors and Actuators, B: Chemical*. **147** (2), 765–774 (2010).
9. Patel, A., Mequanint, K. Hydrogel Biomaterials. *Biomedical Engineering - Frontiers and Challenges*. 275–296 (2012).
10. Kenawy, E., Kamoun, E.A., El-meligy, M.A., Mohy, M.S. Physically crosslinked poly (vinyl alcohol) - hydroxyethyl starch blend hydrogel membranes : Synthesis and characterization for biomedical applications. *Arabian Journal of Chemistry*. **7** (3), 372–380 (2014).
11. Kamoun, E.A., Kenawy, E.R.S., Chen, X. A review on polymeric hydrogel membranes for wound dressing applications: PVA-based hydrogel dressings. *Journal of Advanced Research*. **8** (3), 217–233 (2017).
12. Hassan, C.M., Peppas, N.A. Structure and Morphology of Freeze / Thawed PVA Hydrogels. *Macromolecules*. **33**, 2472–2479 (2000).
13. Tsou, Y.H., Khoneisser, J., Huang, P.C., Xu, X. Hydrogel as a bioactive material to regulate stem cell fate. *Bioactive Materials*. **1** (1), 39–55 (2016).
14. Kumar, A., Mishra, R., Reinwald, Y., Bhat, S. Cryogels: Freezing unveiled by thawing. *Materials Today*. **13** (11), 42–44 (2010).
15. Wu, T., Li, Y., Lee, D.S. Chitosan-based composite hydrogels for biomedical applications. *Macromolecular Research*. **25** (6), 480–488 (2017).
16. Dutta, P.K., Dutta, J., Tripathi, V.S. Chitin and chitosan: Chemistry, properties and applications. *Journal of Scientific and Industrial Research*. **63**, 20–31 (2004).
17. Winnicka, E.S. and K. Stability of Chitosan—A Challenge for Pharmaceutical and Biomedical Applications. *Marine Drugs*. **13**, 1819–1846 (2015).
18. Yang, X., Liu, Q., Chen, X., Yu, F., Zhu, Z. Investigation of PVA/ws-chitosan hydrogels prepared by combined gamma-irradiation and freeze-thawing. *Carbohydrate Polymers*. **73** (3), 401–408 (2008).
19. Mathews, Birbey, Y.A., Cahill, P.A., McGuinness, G.B. Mechanical and Morphological Characteristics of Poly(vinyl alcohol)/Chitosan Hydrogels. *Journal of Applied Polymer Science*. **109**, 1129–1137 (2008).
20. Hosseini, M.S., Amjadi, I., Haghighipour, N. Preparation of Poly(vinyl alcohol)/Chitosan-Blended Hydrogels: Properties, in Vitro Studies and Kinetic Evaluation. *Journal of Biomimetics, Biomaterials, and Tissue Engineering*. **15**, 63–72 (2012).



21. Afshari, M.J., Sheikh, N., Afarideh, H. PVA/CM-chitosan/honey hydrogels prepared by using the combined technique of irradiation followed by freeze-thawing. *Radiation Physics and Chemistry*. **113**, 28–35 (2015).
22. Agnihotri, S., Mukherji, S.S., Mukherji, S.S. Antimicrobial chitosan–PVA hydrogel as a nanoreactor and immobilizing matrix for silver nanoparticles. *Applied Nanoscience*. **2** (3), 179–188 (2012).
23. Yang, X. et al. Cytotoxicity and wound healing properties of PVA/ws-chitosan/glycerol hydrogels made by irradiation followed by freeze-thawing. *Radiation Physics and Chemistry*. **79** (5), 606–611 (2010).
24. Machín, R., Isasi, J.R., Vélaz, I. Hydrogel matrices containing single and mixed natural cyclodextrins. Mechanisms of drug release. *European Polymer Journal*. **49** (12), 3912–3920 (2013).
25. Ritger, P.L., Peppas, N.A. A Simple Equation for Description of Solute Release. *Journal of Controlled Release*. **5**, 37–42 (1987).
26. Abureesh, M.A., Oladipo, A.A., Gazi, M. Facile synthesis of glucose-sensitive chitosan–poly(vinyl alcohol) hydrogel: Drug release optimization and swelling properties. *International Journal of Biological Macromolecules*. **90**, 75–80 (2016).
27. Mansur, H.S., Sadahira, C.M., Souza, A.N., Mansur, A.A.P. FTIR spectroscopy characterization of Poly(vinyl alcohol) hydrogel with different hydrolysis degree and chemically crosslinked with glutaraldehyde. *Materials Science and Engineering C*. **28** (4), 539–548 (2008).
28. Parida, U.K., Nayak, A.K., Binhani, B.K., Nayak, P.L. Synthesis and Characterization of Chitosan-Polyvinyl Alcohol Blended with Cloisite 30B for Controlled Release of the Anticancer Drug Curcumin. *Journal of Biomaterials and Nanobiotechnology*. **02** (04), 414–425 (2011).
29. Zu, Y. et al. Preparation and characterization of chitosan-polyvinyl alcohol blend hydrogels for the controlled release of nano-insulin. *International Journal of Biological Macromolecules*. **50** (1), 82–87 (2012).
30. Lejardi, A., Hernández, R., Criado, M., Santos, J.I., Etxeberria, A., Sarasua, J.R. Novel hydrogels of chitosan and poly (vinyl alcohol) -g-glycolic acid copolymer with enhanced rheological properties. *Carbohydrate Polymers*. **103**, 267–273 (2014).
31. Reis, E.F. dos et al. Synthesis and characterization of Poly(vinyl alcohol) hydrogels and hybrids for rMPB70 protein adsorption. *Materials Research*. **9** (2), 185–191 (2006).
32. Thanyacharoen, T., Chuysinuan, P., Techasakul, S., Nooeaid, P., Ummartyotin, S. Development of a gallic acid-loaded chitosan and polyvinyl alcohol hydrogel composite: Release characteristics and antioxidant activity. *International Journal of Biological Macromolecules*. **107** (PartA), 363–370 (2018).
33. Lozinsky, V.I. et al. Polymeric cryogels as promising materials of biotechnological interest. *Trends in Biotechnology*. **21** (10), 445–451 (2003).
34. Liu, Y., Vrana, N.E., Cahill, P.A., McGuinness, G.B. Physically crosslinked composite hydrogels of PVA with natural macromolecules: Structure, mechanical properties, and endothelial cell compatibility. *Journal of Biomedical Materials Research - Part B Applied Biomaterials*. **90 B** (2), 492–502 (2009).
35. Yang, W. et al. Polyvinyl alcohol/chitosan hydrogels with enhanced antioxidant and antibacterial properties induced by lignin nanoparticles. *Carbohydrate Polymers*. **181** (August 2017), 275–284 (2018).



36. Park, H., Kim, D. Swelling and mechanical properties of glycol chitosan/poly(vinyl alcohol) IPN-type superporous hydrogels. *Journal of Biomedical Materials Research Part A*. **78A** (4), 662–667 (2006).
37. Zhang, H., Zhang, F., Wu, J. Physically crosslinked hydrogels from polysaccharides prepared by freeze-thaw technique. *Reactive and Functional Polymers*. **73** (7), 923–928 (2013).
38. Hassan, C.M., Peppas, N.A. Structure and Applications of Poly (vinyl alcohol) Hydrogels Produced by Conventional Crosslinking or by Freezing / Thawing Methods. *Advances in Polymer Science*. **153**, 37–65 (2000).
39. Sung, J.H. et al. Gel characterisation and in vivo evaluation of minocycline-loaded wound dressing with enhanced wound healing using polyvinyl alcohol and chitosan. *International Journal of Pharmaceutics*. **392** (1–2), 232–240 (2010).
40. Lin, C.C., Metters, A.T. Hydrogels in controlled release formulations: Network design and mathematical modeling. *Advanced Drug Delivery Reviews*. **58** (12–13), 1379–1408 (2006).
41. Fan, L., Yang, H., Yang, J., Peng, M., Hu, J. Preparation and characterization of chitosan/gelatin/PVA hydrogel for wound dressings. *Carbohydrate Polymers*. **146**, 427–434 (2016).
42. Islam, A. et al. Evaluation of selected properties of biocompatible chitosan / poly (vinyl alcohol) blends. *International Journal of Biological Macromolecules*. **82**, 551–556 (2016).
43. Montaser, A.S. Physical, mechanical and antimicrobial evaluations of physically crosslinked PVA/chitosan hydrogels containing nanoparticles. *Journal of Applied Pharmaceutical Science*. **6** (5), 1–6 (2016).
44. Hou, Y., Chen, C., Liu, K., Tu, Y., Zhang, L., Li, Y. Preparation of PVA hydrogel with high-transparency and investigations of its transparent mechanism. *RSC Advances*. **5** (31), 24023–24030 (2015).















Table 1.—Porosimetry parameters of porous structure of CS-PVA hydrogels.

Hydrogel	Total intrusion volume (mL/g)	Total pore area (m ² /g)	Porosity (%)	Permeability (mdarcy)	Tortuosity
CP4-4	5.16	10.19	67.13	132.43	10.46
CP4-80	7.36	15.14	85.95	151.16	5.83
CP6-80	6.69	12.86	84.82	129.28	12.2

Table 2.- Encapsulation and release efficiencies for CS-PVA hydrogels.

Sample	Diflunisal loaded	Diflunisal released	
	mg/g hydrogel	Encapsulati on	% released respect to loaded
CP4-4	3.05± 0.09	71	79 ± 3.33
CP4-80	3.22 ± 0.47	73	86 ± 0.4
CP6-80	3.19 ± 0.05	68	80 ± 3.9

Table 3.-Kinetic parameters of diflunisal release from chitosan-PVA hydrogels.

Sample	Korsmeyer-Peppas			Higuchi		First Order		Zero Order	
	$k_{KP} \times 10^2$ (min ⁻ⁿ)	n	R ²	$k_H \times 10^2$ (min ^{-0.5})	R ²	$k_1 \times 10^2$ (min ⁻¹)	R ²	$k_0 \times 10^2$ (min ⁻¹)	R ²
CP4-4	4.3 ± 0.39	0.44 ± 0.02	0.99	3.1 ± 0.1	0.982	0.29 ± 0.03	0.803	0.18 ± 0.02	0.544
CP4-80	3.6 ± 0.33	0.50 ± 0.02	0.99	3.7 ± 0.1	0.994	0.42 ± 0.03	0.894	0.27 ± 0.02	0.698
CP6-80	2.3 ± 0.24	0.54 ± 0.02	0.99	2.9 ± 0.1	0.989	0.27 ± 0.02	0.925	0.17 ± 0.01	0.767

= kinetic constant; n = diffusion constant

Materials:

Name	Company	Catalog numb	Comments
Chitosan medium molecular weight	Sigma-Aldrich	448877	Mw determined by capillary viscometry (637,000 Da) and deacetylation degree of 70%
Diflunisal (2'-4'-difluoro-4-hydroxy-3-biphenyl-carboxylic acid)	Merck		
Glacial acetic acid	Sigma-Aldrich	1005706	
Poly(vinyl alcohol)	Sigma-Aldrich	341584	Mw 89,000-98,000, 99+% hydrolyzed

Equipment:

Name	Company	Comments
Cressington Sputter Coater 108 auto	TED PELLA INC	
Cryodos Lyophilizer	Telstar	
Falcon tubes	Thermo Fisher	
FT-IR spectroscopy	Nicolet iS50	in ATR mode
Lyophilizer	LABCONCO	
Micromeritics Autopore IV 9500	Micromeritics	
Scanning electron microscope	Pemtron SS-300LV	
UV-visible spectrophotometer	Agilent 8453	



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Freeze-thawing method to prepare chitosan-PLA (vinyl alcohol) hydrogels without crosslinking agents and diffusional release studies.

Author(s):

Maria D. Figuroa-Pizano, Itz'ar Velaz, Maria C. Martinez-Barbosa

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:

☒ Standard Access

☐ Open Access

Item 2: Please select one of the following items:

☒ The Author is **NOT** a United States government employee.

☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.

☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: "Agreement" means this Article and Video License Agreement; "Article" means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; "Author" means the author who is a signatory to this Agreement; "Collective Work" means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; "CRC License" means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; "Derivative Work" means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; "Institution" means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; "JoVE" means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; "Materials" means the Article and / or the Video; "Parties" means the Author and JoVE; "Video" means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to

the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication of the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

CORRESPONDING AUTHOR

Name:

Maria Elisa Martinez-Barbosa

Department:

Departamento de Investigación en Polímeros y Materiales

Institution:

Universidad de Sonora.

Title:

Professor.

Signature:



Date:

December 31th 2018.

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140



"El saber de mis hijos
hará mi grandeza"

UNIVERSIDAD DE SONORA

Departamento de Investigación en Polímeros y
Materiales

May 30th 2019

Dear Phillip Steindel, Ph. D.

JoVE Review Editor

Please, find enclosed the revised manuscript (with all changes remarked in red) for the paper entitled **"Freeze-thawing method to prepare chitosan-poly (vinyl alcohol) hydrogels without crosslinking agents and diflunisal release studies"**.

First of all, we would like to thank the amendments suggested from you and the reviewers. We have taken into account all the corrections received because we have found them very useful. We think the overall quality of the article has been improved and we hope it is a suitable one for its publication.

Next, we include a separate point-by-point response detailing how the revision has been made.

Thank you for your attention.

Best regards,

María Elisa Martínez-Barbosa, Ph.D.

Editorial Comments:

Changes to be made by the author(s):

1. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues. The JoVE editor will not copy-edit your manuscript and any errors in the submitted revision may be present in the published version.

Grammar issues have been corrected as follows:

- The word "Poly(vinyl alcohol)" was changed by "Poly (vinyl alcohol)" overall the manuscript.
- In line 53: "tridimensional" was changed by "three-dimensional".
- In line 55: "physiologic" was changed by "physiological".

Apdo. Postal 130, Edif. 3G, Blvd. Luis Encinas y Rosales S/N, Colonia Centro, C.P. 83000, Hermosillo,
Sonora

Tel. 259-21-61 Fax. 259 22 16 ext. 161 y 308

- d. In line 81: “bounds” was changed by “bonds”.
- e. In line 89: “source with positive charge” was changed by “sources with positive charges”.
- f. In line 93: “cellular” was changed by “cell”.
- g. In line 162: “samples were in vacuum” was changed by “samples under vacuum”.
- h. In line 179: “by” was changed by “with”.

2. **Keywords: Please provide at least 6 keywords or phrases.**

The word “Porosimetry” was added to Keywords.

3. **3. 1.2: How are the solutions mixed? On a stirrer?**

The phrase “mix both solutions 1:1 until” was changed to “mix both solutions 1:1 using a magnetic stirrer” (line 128).

4. **4. 6.3: Please describe how to calculate the encapsulation efficiency.**

The determination of Encapsulation Efficiency (EE) is explained in lines 185-190, and the Equation 3 was added.

5. **JoVE is a methods-based journal. Thus, the discussion section of the article should be focused on the protocol and not on the representative results. Please revise the Discussion to explicitly cover the following in detail in 3-6 paragraphs with citations:**

a) Critical steps in the protocol

b) Modifications and troubleshooting of the method

c) Limitations of the method

d) The significance of the method with respect to existing/alternative methods

e) Future applications or directions of the method

As recommended, in this section (lines 322-368), some phrases concerning the results were eliminated. Indeed, some paragraphs were added focusing the discussion on the critical steps in the protocol, the significance and modifications of the method as well as the limitations. The corresponding citations were inserted.

Reviewers' comments:

Reviewer #1:

Major Concerns:

1. **The Figure 1 should include the chitosan and PVA FTIR curves as controls.**
In Figure 1 (renumbered like Figure 2) the FT-IR of pure chitosan and PVA were included as controls.
2. **In the Figure 2, the scale bar should be included in the SEM pictures. Also, the CP4-80 picture is duplicated. One of the CP4-80 SEM image should be removed. Moreover, the manuscript states that the CP4-4 hydrogel has bigger pores than the CP4-80 hydrogels. However, the CP4-4, CP4-20 and CP4-80 hydrogels seems very similar in SEM.**

In Figure 2 (renumbered like Figure 3) the scale bars are automatically included at the bottom (outside) of each SEM micrograph. Indeed, this figure was restructured in order to eliminate CP4-80 SEM duplication and to conserve the comparison lines (effect of the temperature, left to right; effect of the number of freezing cycles, top to bottom). Finally, porosimetry curves (from the original Figure 3) were inserted in the same Figure (Figures 3-a, 3-b).

Concerning the results, it is true that it is not easy to appreciate the differences between hydrogels CP4-4, CP4-20 and CP4-80 from SEM Images, however these differences can be better appreciated by the porosimetry results.

3. **In the Table 1, how many replicates of measurements were conducted? The standard deviation should be included in the data.**

Porosity measurements were done once, as shown in several works including similar studies, for example:

1. Morgado, P.I. *et al.* Poly(vinyl alcohol)/chitosan asymmetrical membranes: Highly controlled morphology toward the ideal wound dressing. *Journal of Membrane Science*. **469**, 262–271, doi: 10.1016/j.memsci.2014.06.035 (2014).
2. Temtem, M., Barroso, T., Casimiro, T., Mano, J.F., Aguiar-Ricardo, A. Dual stimuli responsive poly(N-isopropylacrylamide) coated chitosan scaffolds for controlled release prepared from a non residue technology. *Journal of Supercritical Fluids*. **66**, 398–404, doi: 10.1016/j.supflu.2011.10.015 (2012).
3. Balaji, S. *et al.* Preparation and comparative characterization of keratin-chitosan and keratin-gelatin composite scaffolds for tissue engineering applications. *Materials Science and Engineering C*. **32** (4), 975–982, doi: 10.1016/j.msec.2012.02.023 (2012).

4. **The release profiles were fitted into different models. However, the model equations were missing in the manuscript. In the Table 3, the n and k values were not defined.**

Moreover, it is not clear how the conclusion of diffusion-controlled release mechanism was made based on the result of fitting.

In section 6.5 the model equations were described (Eq. 4-7). Indeed, in this section, the n and k values were defined (Table 3). Moreover, we describe how to interpret the n values obtained and the procedure to follow to conclude the predominant release mechanisms (lines 202-206).

5. **The manuscript mentioned in multiply places about the crystalline zones formed due to the PVA chain interaction during freeze-thawing process. However, this was not strongly supported by the SEM images of the hydrogels.**

To our knowledge, the crystalline zones formed by polymeric chains couldn't be observed by SEM, even nor by TEM, due either by the resolution needed and also because the polymeric material hasn't the contrast enough. Other techniques can be used for that purpose. However, this characterization was not the objective of our study. In fact, according to the literature, these crystalline zones in the PVA hydrogels are well characterized by Hassan, C.M. and Peppas, N.A. in Structure and Applications of Poly (vinyl alcohol) Hydrogels Produced by Conventional Crosslinking or by Freezing / Thawing Methods. *Advances in Polymer Science*. **153**, 37–65, doi: 10.1007/3-540-46414-X_2 (2000).

Minor Concerns:

1. In Line 181, section 6.3: "Measure the absorbance at 252 nm of the supernatant solutions at 252 nm" has two "at 252 nm".

Thank you, the second "at 252 nm" has been deleted (line 185).

Moreover, this section did not mention about the instrument has been used.

As required in the "Standard Manuscript Template", all the instruments specifications are enlisted in the "Table of Materials" (attached Excel document).

The encapsulation efficiency is not defined in the manuscript.

The Encapsulation Efficiency (EE) was defined by Eq. 3, lines 193.

2. It is better to include the structures of chitosan, PVA and diflunisal in the manuscript.

The structures of chitosan, PVA and diflunisal were included in Figure 1 and cited in lines 78, 92, and 116, respectively. Therefore, all the Figures have been renumbered.

Reviewer #2:

Major Concerns:

1. **The FTIR-ATR spectra did not bring any relevant information.**

FT-IR is a basic characterization for polymeric materials in order to put in evidence the components present in the samples. In this case, even if it is a basic characterization, the FT-IR spectra have not been eliminated, because required by other reviewer, FT-IR spectra of pure chitosan and PVA were added to the Figure 2 as controls.

2. The gel fraction % is necessary


Generally, the gel fraction determination it is made in order to know the percentage of gel remaining after a swelling process, which is related to a degradation process or a dissolution of the polymers, in the short time. This determination it could be made under different conditions depending the purpose of the study, for example a) swelling the hydrogel in a solvent inert to all the hydrogel components, b) swelling the hydrogel in a solvent selective to one of the hydrogel components. However, this characterization was not the objective of our study. In our case, it could be observed (in the swelling graphs) that this could be happened at environ 120 hours of swelling. However, our drug charge and drug release studies were carried out at maximum 30 hours.

3. The drug release and the drug charge are not so clear, how did you do that? With dialysis? Filtered? How did you know that Chi exudates are not present? Or PVA?


In order to explain better the drug release and the drug charge, Section 6 has been restructured (lines 176-217).

Please, show the UV/Vis Spectrum.

In the next figure are shown the UV/Vis Spectrum of buffers solutions after immersion of: a) chitosan-PVA hydrogels without drug , b) chitosan-PVA hydrogels with diflunisal. It could be observed that no chitosan or PVA signals were detected by Uv-Vis, neither another signal that could present any interference in the diflunisal determination.



Also, are presented the UV-Vis spectrums obtained during the drug loading studies for one of the sample, were neither interference of hydrogel components was presented.



4. In the Discussion part it is not clear the differences obtained among the processes condition used. Please, Put references in this part.

As recommended, in this section (lines 322-368), some phrases concerning the results were eliminated. Indeed, some paragraphs were added focusing the discussion on the critical steps in the protocol, the significance and modifications of the method as well as the limitations. The corresponding citations were inserted.

Revised manuscript entitled: “Freeze-thawing method to prepare chitosan-poly (vinyl alcohol) hydrogels without crosslinking agents and diflunisal release studies”.

Answers to Reviewer #1

First of all, we would like to thank the amendments suggested. We have taken into account all the corrections received because we have found them very useful.

Considering the requested corrections, we have made the following changes in the manuscript; all of them are highlighted in red in the document:

Major Concerns:

1. **The Figure 1 should include the chitosan and PVA FTIR curves as controls.**

In Figure 1 (renumbered like Figure 2) the FT-IR of pure chitosan and PVA were included as controls.

2. **In the Figure 2, the scale bar should be included in the SEM pictures. Also, the CP4-80 picture is duplicated. One of the CP4-80 SEM image should be removed. Moreover, the manuscript states that the CP4-4 hydrogel has bigger pores than the CP4-80 hydrogels. However, the CP4-4, CP4-20 and CP4-80 hydrogels seems very similar in SEM.**

In Figure 2 (renumbered like Figure 3) the scale bars are automatically included at the bottom (outside) of each SEM micrograph. Indeed, this figure was restructured in order to eliminate CP4-80 SEM duplication and to conserve the comparison lines (effect of the temperature, left to right; effect of the number of freezing cycles, top to bottom). Finally, porosimetry curves (from the original Figure 3) were inserted in the same Figure (Figures 3-a, 3-b).

Concerning the results, it is true that it is not easy to appreciate the differences between hydrogels CP4-4, CP4-20 and CP4-80 from SEM Images, however these differences can be better appreciated by the porosimetry results.

3. **In the Table 1, how many replicates of measurements were conducted? The standard deviation should be included in the data.**

Porosity measurements were done once, as shown in several works including similar studies, for example:

1. Morgado, P.I. *et al.* Poly(vinyl alcohol)/chitosan asymmetrical membranes: Highly controlled morphology toward the ideal wound dressing. *Journal of Membrane Science*. **469**, 262–271, doi: 10.1016/j.memsci.2014.06.035 (2014).

2. Temtem, M., Barroso, T., Casimiro, T., Mano, J.F., Aguiar-Ricardo, A. Dual stimuli responsive poly(N-isopropylacrylamide) coated chitosan scaffolds for controlled release prepared from a non residue technology. *Journal of Supercritical Fluids*. **66**, 398–404, doi: 10.1016/j.supflu.2011.10.015 (2012).

3. Balaji, S. *et al.* Preparation and comparative characterization of keratin-chitosan and keratin-gelatin composite scaffolds for tissue engineering applications. *Materials Science and Engineering C*. **32** (4), 975–982, doi: 10.1016/j.msec.2012.02.023 (2012).

4. **The release profiles were fitted into different models. However, the model equations were missing in the manuscript. In the Table 3, the n and k values were not defined. Moreover, it is not clear how the conclusion of diffusion-controlled release mechanism was made based on the result of fitting.**

In section 6.5 the model equations were described (Eq. 4-7). Indeed, in this section, the *n* and *k* values were defined (Table 3). Moreover, we describe how to interpret the *n* values obtained and the procedure to follow to conclude the predominant release mechanisms (lines 202-206).

5. **The manuscript mentioned in multiply places about the crystalline zones formed due to the PVA chain interaction during freeze-thawing process. However, this was not strongly supported by the SEM images of the hydrogels.**

To our knowledge, the crystalline zones formed by polymeric chains couldn't be observed by SEM, even nor by TEM, due either by the resolution needed and also because the polymeric material hasn't the contrast enough. Other techniques can be used for that purpose. However, this characterization was not the objective of our study. In fact, according to the literature, these crystalline zones in the PVA hydrogels are well characterized by Hassan, C.M. and Peppas, N.A. in Structure and Applications of Poly (vinyl alcohol) Hydrogels Produced by Conventional Crosslinking or by Freezing / Thawing Methods. *Advances in Polymer Science*. **153**, 37–65, doi: 10.1007/3-540-46414-X_2 (2000).

Minor Concerns:

- 1. In Line 181, section 6.3: "Measure the absorbance at 252 nm of the supernatant solutions at 252 nm" has two "at 252 nm".**

Thank you, the second “at 252 nm” has been deleted (line 185).

- Moreover, this section did not mention about the instrument has been used.**

As required in the “Standard Manuscript Template”, all the instruments specifications are enlisted in the “Table of Materials” (attached Excel document).

- The encapsulation efficiency is not defined in the manuscript.**

The Encapsulation Efficiency (EE) was defined by Eq. 3, lines 193.

2. It is better to include the structures of chitosan, PVA and diflunisal in the manuscript

The structures of chitosan, PVA and diflunisal were included in Figure 1 and cited in lines 78, 92, and 116, respectively. Therefore, all the Figures have been renumbered.

Revised manuscript entitled: “Freeze-thawing method to prepare chitosan-poly (vinyl alcohol) hydrogels without crosslinking agents and diflunisal release studies”.

Answers to Reviewer #2

First of all, we would like to thank the amendments suggested. We have taken into account all the corrections received because we have found them very useful.

Considering the requested corrections, we have made the following changes in the manuscript; all of them are highlighted in red in the document:

Major Concerns:

1. The FTIR-ATR spectra did not bring any relevant information.

FT-IR is a basic characterization for polymeric materials in order to put in evidence the components present in the samples. In this case, even if it is a basic characterization, the FT-IR spectra have not been eliminated, because required by other reviewer, FT-IR spectra of pure chitosan and PVA were added to the Figure 2 as controls.

2. The gel fraction % is necessary


Generally, the gel fraction determination it is made in order to know the percentage of gel remaining after a swelling process, which is related to a degradation process or a dissolution of the polymers, in the short time. This determination it could be made under different conditions depending the purpose of the study, for example a) swelling the hydrogel in a solvent inert to all the hydrogel components, b) swelling the hydrogel in a solvent selective to one of the hydrogel components. However, this characterization was not the objective of our study. In our case, it could be observed (in the swelling graphs) that this could be happened at environ 120 hours of swelling. However, our drug charge and drug release studies were carried out at maximum 30 hours.

3. The drug release and the drug charge are not so clear, how did you do that? With dialysis? Filtered? How did you know that Chi exudates are not present? Or PVA?


In order to explain better the drug release and the drug charge, Section 6 has been restructured (lines 176-217).

Please, show the UV/Vis Spectrum.

In the next figure are shown the UV/Vis Spectrum of buffers solutions after immersion of: a) chitosan-PVA hydrogels without drug , b) chitosan-PVA hydrogels with diflunisal. It could be observed that no chitosan or PVA signals were detected by Uv-Vis, neither another signal that could present any interference in the diflunisal determination.



Also, are presented the UV-Vis spectrums obtained during the drug loading studies for one of the sample, were neither interference of hydrogel components was presented.



4. In the Discussion part it is not clear the differences obtained among the processes condition used. Please, Put references in this part.

As recommended, in this section (lines 322-368), some phrases concerning the results were eliminated. Indeed, some paragraphs were added focusing the discussion on the critical steps in the protocol, the significance and modifications of the method as well as the limitations. The corresponding citations were inserted.